Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study

被引:20
|
作者
Wu, Simon [1 ,2 ]
Chee, Desmond [1 ,2 ]
Ugalde, Anna [1 ,3 ]
Butow, Phyllis [4 ]
Seymour, John [2 ,5 ]
Schofield, Penelope [1 ,2 ,6 ]
机构
[1] Peter MacCallum Canc Ctr, Dept Canc Experiences Res, East Melbourne, Vic, Australia
[2] Univ Melbourne, Fac Med Dent & Hlth Sci, Parkville, Vic 3052, Australia
[3] St Vincents Hosp Melbourne, Ctr Palliat Care, Fitzroy, Vic, Australia
[4] Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia
[5] Peter MacCallum Canc Ctr, Dept Hematol, East Melbourne, Vic, Australia
[6] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia
基金
英国医学研究理事会;
关键词
Cancer; Adherence; Chronic myeloid leukemia; Qualitative; Imatinib; DOWNWARD EVALUATION; FOLLOW-UP; COMPLEMENTARY; MEDICINE; CANCER; INTERVENTIONS; ONCOLOGISTS; REGIMENS; BEHAVIOR;
D O I
10.1017/S1478951513001260
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Consistent use of imatinib is critical for treatment success in chronic myeloid leukemia, yet perfect adherence to the prescribed clinical regimen is reported to be as low as 14%. This study aimed to understand patients' experiences of chronic myeloid leukemia with a qualitative approach, including identified facilitators and barriers to adherence, drawing on patients' and health professionals' perspectives, recording comments made by patients and health professionals involved with the same treatment team. Method: We recruited patients with chronic myeloid leukemia prescribed imatinib therapy and health professionals involved in their treatment from a specialized cancer center. Semi-structured qualitative interviews were recorded, transcribed, and manually analyzed using interpretive phenomenological analysis. Recruitment ceased upon saturation, with 16 patients and 10 health professionals (hematologists n = 4, nurses n = 3, pharmacists n = 3). Results: Twelve patients reported at least one instance of nonadherence. Reasons for unintentional nonadherence included forgetfulness related to variations of routine and doctor-patient communication issues. Reasons for intentional nonadherence included desires to reduce dose-dependent side effects and insufficient support. Patients who reported higher nonadherence rates felt complacent following periods of sustained disease control or had received conflicting advice regarding nonadherence. Health professionals had difficulty in accurately evaluating medication adherence due to a lack of reliable measures, utilizing patient self-report and manifestations of suboptimal disease control to guide assessments. Significance of Results: Adherence issues persist throughout the course of treatment. While high patient-reported nonadherence rates were recorded, health professionals were often unaware of the complex causes, compounded by an inadequacy of adherence assessment tools. Some patients reported nonadherence events because of insufficient education or lack of access to prompt medical guidance. These issues should be addressed to improve clinical practice.
引用
收藏
页码:255 / 263
页数:9
相关论文
共 50 条
  • [31] Treatment outcome of patients receiving imatinib for chronic myeloid leukemia as first or second line therapy
    De Souza, C. A.
    Pagnano, K. B. B.
    Delamain, M. T.
    Lorand-Metze, I.
    Miranda, E. C. M.
    Silveira, R. A.
    Metze, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 535 - 535
  • [32] Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia
    Cole, Ashley L.
    Jazowski, Shelley A.
    Dusetzina, Stacie B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (11) : 1529 - 1533
  • [33] Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
    Al-Dewik, N. Ader I.
    Morsi, Hisham M.
    Samara, Muthanna M.
    Ghasoub, Rola S.
    Gnanam, Cinquea C.
    Bhaskaran, Subi K.
    Nashwan, Abdulqadir J.
    Al-Jurf, Rana M.
    Ismail, Mohamed A.
    AlSharshani, Mohammed M.
    AlSayab, Ali A.
    Ben-Omran, Tawfeg I.
    Khatib, Rani B.
    Yassin, Mohamed A.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 95 - 104
  • [34] The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib
    Omran, Mervat M.
    Ibrahim, Amel B.
    Abdelfattah, Raafat
    Moussa, Heba S.
    Shouman, Samia A.
    Hamza, Marwa S.
    LEUKEMIA & LYMPHOMA, 2025, 66 (01) : 123 - 130
  • [35] Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
    Wu, Eric Q.
    Johnson, Scott
    Beaulieu, Nicolas
    Arana, Mateo
    Bollu, Vamsi
    Guo, Amy
    Coombs, John
    Feng, Weiwei
    Cortes, Jorge
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (01) : 61 - 69
  • [36] Imatinib sets new treatment standard in patients with chronic myeloid leukemia
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (08): : 935 - 936
  • [37] Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients
    Singh, Avinash Kumar
    Vidyadhari, Arya
    Bhurani, Dinesh
    Agrawal, Narendra
    Ahmed, Rayaz
    Sharma, Manju
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (08) : 1928 - 1934
  • [38] Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
    Noens, Lucien
    van Lierde, Marie-Anne
    De Bock, Robrecht
    Verhoef, Gregor
    Zachee, Pierre
    Berneman, Zwi
    Martiat, Philippe
    Mineur, Philippe
    Van Eygen, Koen
    MacDonald, Karen
    De Geest, Sabina
    Albrecht, Tara
    Abraham, Ivo
    BLOOD, 2009, 113 (22) : 5401 - 5411
  • [39] Patient-Reported Outcomes and Adherence to Long Term Therapy with Imatinib in Patients with Chronic Myeloid Leukemia. (FR)
    Collone, Francesco
    Baccarani, Michele
    Breccia, Massimo
    Alimena, Giuliana
    Rosti, Gianantonio
    Fausto, Castagnetti
    Vignetti, Marco
    Mandelli, Franco
    Efficace, Fabio
    QUALITY OF LIFE RESEARCH, 2012, 20 : 45 - 45
  • [40] Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia
    Anderson, Kristin R.
    Chambers, Carole R.
    Lam, Nadine
    Yau, Patrick S.
    Cusano, Frances
    Savoie, M. Lynn
    Sheikh, Naureen
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (01) : 19 - 25